Clinical Trials Logo

Ascending Aortic Dissection clinical trials

View clinical trials related to Ascending Aortic Dissection.

Filter by:
  • None
  • Page 1

NCT ID: NCT05927090 Enrolling by invitation - Clinical trials for Aortic Valve Insufficiency

Outcomes of Type A Aortic Dissection Repair

STAAD
Start date: January 1, 2005
Phase:
Study type: Observational [Patient Registry]

Type A aortic dissection (TAAD) is a potentially life-threatening pathology associated with significant risk of mortality and morbidity. In acute forms of type A aortic dissection (TAAD) mortality is 50% by 24 h and 50% of patients die before reaching a specialist center. Rapid diagnosis and subsequent prompt surgical repair remain the primary goal for these patients. In the last decade it has been observed that improvements in diagnostic techniques, initial management and increased clinical awareness have contributed to a substantial increase in the number of patients benefiting from a prompt diagnosis and undergoing surgery.However, survival after surgical repair has not yet reached optimal follow-ups and is burdened by high in-hospital mortality(16-18%)

NCT ID: NCT04544579 Not yet recruiting - Clinical trials for Ascending Aortic Dissection

Endovascular Graft Anchoring Different Regions of Ascending Aorta in the Treatment of Ascending Aortic Dissection

Start date: October 1, 2020
Phase:
Study type: Observational

Aortic dissection is a deadly and dangerous disease. About 28% of patients with ascending aortic dissection can't tolerate open surgical trauma caused by thoracotomy and cardiopulmonary bypass, and the prognosis is poor. Minimally invasive endovascular treatment has been applied in the treatment of descending aortic dissection. However, due to the special anatomical structure and high speed /pressure blood flow, the treatment of ascending aorta dissection has become an international difficulty.

NCT ID: NCT03917862 Recruiting - Clinical trials for Ascending Aorta Aneurysm

Strategy for Aortic Surgery Hemostasis

SASH
Start date: December 4, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

SASH Trial is a multicenter, prospective, open and randomized 1:1 study. The aim of this study is to evaluate the efficacy of TDM-621(Three-D Matrix- 621) (PuraStat®) on hemostasis of ascending aortic surgery. The TDM-621 is a topic hemostatic product. When in contact with blood it allowed to cover the sutures improving the hemostasis. The hypothesis is that the use of TDM-621 may reduce bleeding and the need for blood transfusion of patients undergoing ascending aortic surgeries. It will include 200 consecutive patients randomized to receive TDM-621 or regular procedure, performed in 5 different centers.

NCT ID: NCT00583817 Enrolling by invitation - Aortic Dissection Clinical Trials

Endovascular Treatment of Thoracic Aortic Disease

EVOLVE Aorta
Start date: October 25, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the role endovascular therapy to treat aortic disease involving the ascending aorta, the aortic arch, and the visceral segment of the aorta (or thoracoabdominal aorta)